Equities

Lepu Biopharma Co Ltd

Lepu Biopharma Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (HKD)3.10
  • Today's Change0.17 / 5.80%
  • Shares traded3.75m
  • 1 Year change-38.86%
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024 09:08 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of CNY
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments490669205
Total Receivables, Net55250.10
Total Inventory292424
Prepaid expenses948576
Other current assets, total8.738.759.05
Total current assets677813314
Property, plant & equipment, net1,0871,039978
Goodwill, net535353
Intangibles, net382398422
Long term investments127122138
Note receivable - long term59104176
Other long term assets------
Total assets2,3842,5292,082
LIABILITIES
Accounts payable208166159
Accrued expenses313125
Notes payable/short-term debt000
Current portion long-term debt/capital leases45839079
Other current liabilities, total204256286
Total current liabilities900844549
Total long term debt284293252
Total debt742684331
Deferred income tax383838
Minority interest(8.21)010
Other liabilities, total274454396
Total liabilities1,4871,6281,245
SHAREHOLDERS EQUITY
Common stock1,6591,6591,532
Additional paid-in capital2,4202,4201,842
Retained earnings (accumulated deficit)(3182)(3179)(2537)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total------
Total equity897901837
Total liabilities & shareholders' equity2,3842,5292,082
Total common shares outstanding1,6591,6591,678
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.